CORRESP Filing
RedHill Biopharma Ltd.
Date: June 30, 2025 · CIK: 0001553846 · Accession: 0001178913-25-002258
AI Filing Summary & Sentiment
File numbers found in text: 333-288324
Show Raw Text
CORRESP 1 filename1.htm RedHill Biopharma Ltd. 21 Ha'arba'a Street Tel Aviv, 6473921, Israel June 30, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street N.E. Washington, D.C. 20549 Attention: Lauren Hamill Re: RedHill Biopharma Ltd. Registration Statement on Form F-1 Filed June 25, 2025 File No. 333-288324 (the “ Registration Statement ”) Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, RedHill Biopharma Ltd. (the “ Company ”) hereby respectfully requests that the effective date of the Company’s Registration Statement be accelerated by the Securities and Exchange Commission to 4:00 p.m., Eastern Time on July 2, 2025, or as soon thereafter as practicable. The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to the Company’s counsel, Haynes and Boone, LLP, by calling Jayun Koo at (212) 835-4823, and that such effectiveness also be confirmed in writing. Very truly yours, REDHILL BIOPHARMA LTD. By: /s/ Dror Ben-Asher Dror Ben-Asher Chief Executive Officer and Chairman of the Board of Directors cc: Rick A. Werner, Esq., Haynes and Boone, LLP Jayun Koo, Esq., Haynes and Boone, LLP